{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:51:52Z","timestamp":1769219512215,"version":"3.49.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To address improvements in quality of life, we analysed the relative contributions of factors to EuroQol 5 Dimensions (EQ-5D) in abatacept-treated rheumatoid arthritis patients in the Orencia\u00ae Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients who were evaluable for disease activity through to\u2009 Week 52 in the ORIGAMI study were divided into those achieving Simplified Disease Activity Index-remission\/low disease activity (remission\/LDA; n\u2009=\u2009178) and patients with moderate disease activity\/high disease activity (MDA\/HDA; n\u2009=\u200999). We compared the changes in EQ-5D and other outcomes through to Week 52. Focusing on the remission\/LDA group, the contribution of each factor to the variance of EQ-5D at baseline and Week 52 was examined using analysis of variance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The remission\/LDA group showed greater improvements than the MDA\/HDA group in EQ-5D, Japanese Health Assessment Questionnaire, visual analogue scale for pain (Pain VAS), and patient\u2019s global assessment (PtGA). In the remission\/LDA group, factors significantly contributing to EQ-5D were sex, C-reactive protein, and Pain VAS at baseline, and PtGA and age at Week 52.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In rheumatoid arthritis patients who achieved remission\/LDA during abatacept treatment, PtGA and age at Week 52 contribute to the variance of EQ-5D, suggesting that the identification of factors associated with PtGA may be important to address improvements in quality of life.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/road082","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T16:50:02Z","timestamp":1692982202000},"page":"686-692","source":"Crossref","is-referenced-by-count":1,"title":["Contribution of\u00a0the factors to EuroQol 5 Dimensions in\u00a0rheumatoid arthritis patients achieving low disease activity\/remission with abatacept treatment: <i>Post hoc<\/i> subgroup analyses of\u00a0the Japanese real-world observational \u2018ORIGAMI\u2019 study"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"},{"name":"Showa University Research Administration Center, Showa University , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Misaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kita-Harima Medical Center , Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Azuma","sequence":"additional","affiliation":[{"name":"Azuma Rheumatology Clinic , Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminori","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, NHO Asahikawa Medical Center , Hokkaido, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Bayside Misato Medical Center , Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mitsuhashi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yokohama Minami Kyousai Hospital , Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shimane University Hospital , Shimane, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Oribe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oribe Rheumachika Naika Clinic , Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Aoki","sequence":"additional","affiliation":[{"name":"Aoki Medical Clinic , Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiaki","family":"Kadode","sequence":"additional","affiliation":[{"name":"Medical Affairs, Ono Pharmaceutical Co., Ltd. , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuki","family":"Tsuritani","sequence":"additional","affiliation":[{"name":"Japan Medical, Bristol Myers Squibb K.K. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"},{"name":"Department of Rheumatology, Sanno Medical Center , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"2024070612131517400_R1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2024070612131517400_R2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of\u00a0an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024070612131517400_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of\u00a0rheumatoid arthritis, IORRA: providing context for\u00a0today\u2019s treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2024070612131517400_R4","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3899\/jrheum.141575","article-title":"Patients with rheumatoid arthritis in\u00a0the Australian OPAL cohort show significant improvement in\u00a0disease activity over 5 years: a multicenter observational study","volume":"42","author":"Littlejohn","year":"2015","journal-title":"J Rheumatol"},{"key":"2024070612131517400_R5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40744-022-00441-0","article-title":"Towards a better implementation of\u00a0treat-to-target strategy in\u00a0rheumatoid arthritis: a comparison of\u00a0two real-world cohorts","volume":"9","author":"Huang","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2024070612131517400_R6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.37897\/RJR.2020.1.2","article-title":"Data from the Romanian registry of\u00a0rheumatic diseases for\u00a0patients with rheumatoid arthritis treated with biologic and\u00a0targeted synthetic disease-modifying anti-rheumatic drugs during 2019","volume":"29","author":"Codreanu","year":"2020","journal-title":"Rom J Rheumatol"},{"key":"2024070612131517400_R7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000019","article-title":"Patient-reported outcomes as end points in\u00a0clinical trials in\u00a0rheumatoid arthritis","volume":"1","author":"Gossec","year":"2015","journal-title":"RMD Open"},{"key":"2024070612131517400_R8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.rdc.2016.01.010","article-title":"Patient-reported outcomes in\u00a0rheumatoid arthritis","volume":"42","author":"van Tuyl","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2024070612131517400_R9","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-12-102","article-title":"Comparative efficacy of\u00a0biologics as monotherapy and\u00a0in combination with methotrexate on\u00a0patient reported outcomes (PROs) in\u00a0rheumatoid arthritis patients with an inadequate response to conventional DMARDs\u2014a systematic review and\u00a0network meta-analysis","volume":"12","author":"Jansen","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"2024070612131517400_R10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031246","article-title":"Janus kinase inhibitors improve disease activity and\u00a0patient-reported outcomes in\u00a0rheumatoid arthritis: a systematic review and\u00a0meta-analysis of\u00a024,135 patients","volume":"23","author":"T\u00f3th","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024070612131517400_R11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/14397595.2017.1416940","article-title":"Residual symptoms and\u00a0disease burden among patients with rheumatoid arthritis in\u00a0remission or low disease activity: a systematic literature review","volume":"28","author":"Ishida","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2024070612131517400_R12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2169\/naika.105.451","article-title":"Rheumatoid arthritis in\u00a0the clinical setting: rheumatoid arthritis from the eyes of\u00a0an internist","volume":"105","author":"Yamanaka","year":"2016","journal-title":"J Jpn Soc Intern Med"},{"key":"2024070612131517400_R13","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-015-0501-8","article-title":"Patient reported outcomes in\u00a0rheumatoid arthritis clinical trials","volume":"17","author":"Orbai","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"2024070612131517400_R14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and\u00a0recommendations from the 2020 update of\u00a0the Japan College of\u00a0Rheumatology clinical practice guidelines for\u00a0the management of\u00a0rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024070612131517400_R15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3109\/14397595.2015.1059983","article-title":"Profiles of\u00a0EQ-5D utility scores in\u00a0the daily practice of\u00a0Japanese patients with rheumatoid arthritis; analysis of\u00a0the IORRA database","volume":"26","author":"Hoshi","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2024070612131517400_R16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/mr\/roac053","article-title":"Subjective symptoms contributing to the quality of\u00a0life of\u00a0rheumatoid arthritis patients with clinical remission from the IORRA database","volume":"33","author":"Sakai","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024070612131517400_R17","article-title":"Association between patient-reported outcomes and\u00a0impairments in\u00a0work and\u00a0activity in\u00a0patients with rheumatoid arthritis in\u00a0clinical remission: a retrospective analysis using the IORRA database","author":"Sakai","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024070612131517400_R18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2147\/tcrm.2006.2.4.365","article-title":"Abatacept in\u00a0the treatment of\u00a0rheumatoid arthritis","volume":"2","author":"Vital","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"2024070612131517400_R19","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in\u00a0rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"2024070612131517400_R20","first-page":"157","article-title":"Efficacy and\u00a0safety of\u00a0abatacept, adalimumab, and\u00a0etanercept in\u00a0paediatric patients with juvenile idiopathic arthritis","volume":"26","author":"Goettel","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2024070612131517400_R21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/mr\/roab090","article-title":"Effectiveness and\u00a0safety of\u00a0subcutaneous abatacept in\u00a0biologic-na\u00efve RA patients at week 52: a Japanese multicentre investigational study (ORIGAMI study)","volume":"32","author":"Tamura","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024070612131517400_R22","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and\u00a0the Clinical Disease Activity Index (CDAI): a review of\u00a0their usefulness and\u00a0validity in\u00a0rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2024070612131517400_R23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/1756-185X.14066","article-title":"Health-related quality of\u00a0life in\u00a0rheumatoid arthritis: systematic review and\u00a0meta-analysis of\u00a0EuroQoL (EQ-5D) utility scores from Asia","volume":"24","author":"Haridoss","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2024070612131517400_R24","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1136\/annrheumdis-2012-201519","article-title":"Near misses of\u00a0ACR\/EULAR criteria for\u00a0remission: effects of\u00a0patient global assessment in\u00a0Boolean and\u00a0index-based definitions","volume":"71","author":"Studenic","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2024070612131517400_R25","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/art.34543","article-title":"Discrepancies between patients and\u00a0physicians in\u00a0their perceptions of\u00a0rheumatoid arthritis disease activity","volume":"64","author":"Studenic","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024070612131517400_R26","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1151-6","article-title":"Patient global assessment in\u00a0measuring disease activity in\u00a0rheumatoid arthritis: a review of\u00a0the literature","volume":"18","author":"Nikiphorou","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024070612131517400_R27","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10067-015-2968-0","article-title":"Interplay between patient global assessment, pain, and\u00a0fatigue and\u00a0influence of\u00a0other clinical disease activity measures in\u00a0patients with active rheumatoid arthritis","volume":"34","author":"Egsmose","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2024070612131517400_R28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/ggi.14375","article-title":"Influence of\u00a0frailty on\u00a0patient global assessment in\u00a0rheumatoid arthritis","volume":"22","author":"Suzuki","year":"2022","journal-title":"Geriatr Gerontol Int"},{"key":"2024070612131517400_R29","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/ard.2005.037903","article-title":"Impact of\u00a0age and\u00a0comorbidities on\u00a0the criteria for\u00a0remission and\u00a0response in\u00a0rheumatoid arthritis","volume":"64","author":"Krishnan","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2024070612131517400_R30","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002022","article-title":"Comprehensive assessment of\u00a0multimorbidity burden in\u00a0a population-based cohort of\u00a0patients with rheumatoid arthritis","volume":"8","author":"Crowson","year":"2022","journal-title":"RMD Open"},{"key":"2024070612131517400_R31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of\u00a0subcutaneous abatacept versus adalimumab for\u00a0rheumatoid arthritis: two-year efficacy and\u00a0safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024070612131517400_R32","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/annrheumdis-2015-207784","article-title":"Comparison of\u00a0the efficacies of\u00a0abatacept and\u00a0tocilizumab in\u00a0patients with rheumatoid arthritis by propensity score matching","volume":"75","author":"Kubo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024070612131517400_R33","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1179-7","article-title":"Comparative effectiveness of\u00a0abatacept versus tocilizumab in\u00a0rheumatoid arthritis patients with prior TNFi exposure in\u00a0the US Corrona registry","volume":"18","author":"Harrold","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024070612131517400_R34","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of\u00a0upadacitinib or abatacept in\u00a0rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"2024070612131517400_R35","article-title":"Patient-reported outcomes of\u00a0upadacitinib versus abatacept in\u00a0patients with rheumatoid arthritis and\u00a0an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and\u00a024-week results of\u00a0a phase 3 trial","volume":"24","author":"Bergman","year":"2022","journal-title":"Arthritis Res Ther"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/road082\/51329882\/road082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/4\/686\/58462949\/road082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/4\/686\/58462949\/road082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T12:13:43Z","timestamp":1720268023000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/4\/686\/7250913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8,25]]},"published-print":{"date-parts":[[2024,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/road082","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2023,8,25]]}}}